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insurance, physician type, region, pre-dialysis co-morbidities, and pre-dialysis costs 
were used to evaluate the impact of pre-dialysis paricalcitol treatment on hospitaliza-
tions, outpatient services, and medication use in ﬁrst year of dialysis. RESULTS: 
Multivariable analysis demonstrated predialysis paricalcitol use was associated 
with statistically signiﬁcant reductions in all-cause hospitalizations (0.806, 95%CI: 
0.684–0.950), all-cause outpatient services (0.953, 95%CI: 0.933–0.973) and CKD-
related hospitalizations (0.780, 95% CI: 0.635 – 0.958); CKD-related outpatient 
visits (0.962, 95% CI: 0.938–0.987); and CKD-related medications (0.922, 95% CI: 
0.852–0.996) in the ﬁrst year of dialysis compared with no predialysis VDR activator 
treatment. CONCLUSIONS: Paricalcitol treatment for SHPT prior to dialysis is 
associated with fewer CKD-related medications; and all-cause and CKD-related out-
patient services and hospitalizations in the ﬁrst year of dialysis compared to no VDR 
activator treatment. Payers should consider these ﬁndings when make coverage deci-
sions regarding the use of paricalcitol. Further studies are needed to conﬁrm these 
results.
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OBJECTIVES: The Combination of Avodart® and Tamsulosin (CombAT) study 
shows that combination therapy provides a signiﬁcantly greater degree of beneﬁt than 
tamsulosin or dutasteride monotherapy in the treatment of moderate to severe benign 
prostatic hyperplasia (BPH). The objective of this study was to assess the cost-effec-
tiveness of combination therapy with tamsulosin and dutasteride relative to either of 
monotherapies using recent information from the CombAT study. METHODS: A 
decision analytic model was constructed using a Markov model and a 1-year cycle 
time to estimate the clinical and cost consequences of tamsulosin, dutasteride, and 
combination therapy. Analyses were conducted for a 20-year time frame from the 
societal perspective. All costs are presented in 2009 US dollars, and costs and outcomes 
were discounted at a rate of 3% per year. Outcomes were expressed in terms of the 
incremental cost-effectiveness ratio (ICER), deﬁned as the ratio of additional costs to 
additional QALYs. Sensitivity analyses were conducted on model probabilities, cost 
estimates, utility values and the discount rate. RESULTS: At both moderate and severe 
symptom levels, tamsulosin was dominated by dutasteride, that is, more costly and 
less effective than dutasteride. Compared to dutasteride, combination therapy was 
more expensive but more effective with the ICERs of $197,625 for moderate symp-
toms and $241,032 for severe symptoms. However, considering a societal cost-effec-
tiveness threshold of $150,000 per QALY, combination therapy was not cost-effective 
compared to dutasteride. In most sensitivity analyses, these results were not sensitive 
to changes in model parameters. CONCLUSIONS: This study showed that tamsulosin 
was more costly and less effective than dutasteride, and the ICERs for combination 
therapy compared to dutasteride were higher than the cost-effectiveness threshold. 
Therefore, combination therapy is not cost-effective relative to dutasteride for 
moderate-to-severe BPH patients.
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OBJECTIVES: Hyperactive Bladder (HB) is a common, debilitating condition with a 
considerable negative impact on quality of life. The cost-effectiveness (CE) of three 
medications was evaluated for the treatment of patients with Hyperactive Bladder 
from the Mexican Institute of Social Security (IMSS) perspective. METHODS: CE 
analysis from the perspective of the service provider (IMSS). Since it is a chronic disease 
with different stages, a Markov model with monthly cycles in a 12-month temporal 
horizon was developed. Only direct medical costs were used in the analysis. Direct 
medical costs were estimated on a sample of patient ﬁles in two IMSS medical units. 
Criteria for inclusion was patients with more than 6 months of treatment. The effec-
tiveness measurement was taken from literature and was deﬁned as the percentage of 
patients that did not present symptoms of incontinence. Univariated and probabilistic 
sensitivity analyses were performed. RESULTS: The oxybutynin treatment reﬂected 
the lowest expected cost per patient treated for hyperactive bladder, US$545 (1 USD 
= 13.5MXN); followed by the solifenacin and tolterodine treatments, with a cost of 
US$680 and US$1,135, respectively. As for the effectiveness measurement, the percent-
age of patients that did not present incontinence within the temporal horizon of analysis 
was: with tolterodine 2.76%, with oxybutynin 7.11% and with solifenacin 7.46%. 
Therefore, cost effectiveness ratios interpreted as the cost per percentage point of 
patients that did not present HB are: oxybuynin US$77, solifenacin US$91 and tol-
terodine US$411. The incremental cost effectiveness analysis indicates that tolterodine 
is a dominated alternative and that oxybutynin and solifenacin are positioned 
within the efﬁciency line. Nonetheless, when conducting the probabilistic analysis, it 
was found that with US$411 available, a solifenacin treatment would be more cost 
effective for the institution. CONCLUSIONS: From an institutional perspective, solif-
enacine is a cost-effective alternative for treating patients with HB in the Mexican 
context.
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OBJECTIVES: To compare the relative cost-effectiveness of three clinical strategies 
for managing T1a tumor (4 cm or smaller and limited to the kidney): early surgery 
upon detection of the tumor, adding percutaneous biopsy prior to surgery, and watch-
ful waiting (WW) (monitor with computerized tomography every 6 months until the 
growth is greater than 2mm per year). METHODS: A Markov decision tree was used 
to estimate the expected survival in quality-adjusted life years (QALYs) and incremen-
tal cost-effectiveness (ICER) for each strategy from a societal perspective, based on 
literature-derived estimates for the probabilities and costs of different outcomes. 
Multiple one-way and probabilistic sensitivity analysis were conducted to examine the 
robustness of the results. RESULTS: In the base-case, adding biopsy before surgery 
improved survival by 0.018 QALYs compared with immediate surgery, at an incre-
mental cost of $55,244/QALY, while the ICER of WW relative to surgery was 
$11,712/QALY. In the base-case, percutaneous biopsy is more expensive and less 
effective than WW. The treatment decision was most sensitive to variation of the 
degree of tumor growth that triggers surgery, utility of living with a mass during WW, 
and the probability of diagnostic biopsy for benign tumors. Choice of WW versus 
surgery critically depends on patients’ preferences for tumor removal and the risk of 
recurrence post surgery. In probabilistic sensitivity analysis, surgery was the most 
favored strategy when the willingness to pay (WTP) is less than $10,000/QALY. WW 
is favored as WTP increases beyond $10,000/QALY, and biopsy was favored over 
surgery when WTP is > $60,000. CONCLUSIONS: Although WW results in the 
highest life-time utility, the favorability of WW depends on patients’ preferences for 
living with a possibly malignant mass and natural history of watched masses during 
surveillance, which are poorly understood. Biopsy would be favored if its costs 
decrease and diagnostic certainty increases in the future.
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OBJECTIVES: Therapies that extend the lives of dialysis patients can not demonstrate 
cost-effectiveness if dialysis costs are included. This study examined the cost-effective-
ness of sevelamer versus calcium-based binders (CBBs) as treatment for hyperphos-
phatemia in dialysis patients and, within this context, the suitability of the inclusion 
of dialysis costs. METHODS: A Markov model estimated life years, incremental cost 
per life year gained (LYG) and incremental quality-adjusted life year gained (QALYG). 
Treatment-speciﬁc survival was derived from the Dialysis Clinical Outcomes Revisited 
(DCOR) study and extrapolated using a Weibull regression model. The base case 
analysis used resource use and survival data for DCOR patients ≥65 years combined 
with Canadian unit costs and utility weights from published literature. Dialysis costs 
were excluded from the base case analysis, as dialysis use is unrelated to phosphate 
binder choice. Analyses were conducted for a 10-year time horizon using the Alberta 
Health Care System perspective, with costs and outcomes discounted at 5% per year. 
RESULTS: Compared with CBBs, sevelamer resulted in a gain of 1.02 LYs and 
0.62 QALYs/ patient (discounted) producing ratios of $20,847/LYG and $34,175/
QALYG. Over a lifetime horizon, the cost/LYG and cost/QALYG were $23,804 and 
$39,022, respectively. Inclusion of dialysis costs resulted in ratios above $90,000/LYG 
and $150,000/QALYG. CONCLUSIONS: The study highlights the challenges associ-
ated with assessing funding of therapies that extend life in dialysis patients and dis-
cusses the applicability of dialysis costs in such situations. It found that sevelamer 
offers good value for money compared to CBBs in the treatment of hyperphosphatemia 
in patients ≥65 years old receiving dialysis.
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OBJECTIVES: Six pharmacological agents are FDA-approved to treat urinary incon-
tinence, a condition that has economic costs of $19 billion US dollars per year. This 
study compares the recently FDA-approved fesoterodine to generic oxybutynin 
extended-release (ER) to identify which agent is more cost-effective in the treatment 
of urinary incontinence for three months in women over age 60 from the third party 
payer perspective. METHODS: A search was conducted using the MEDLINE Data-
base from 1980–2009 for the terms “oxybutynin,” “fesoterodine,” “randomized 
controlled trial,” and “urinary incontinence.” Five articles evaluating clinical improve-
ment among a predominantly female population were identiﬁed for inclusion. For the 
purpose of this analysis, an effectively treated patient was deﬁned as a patient dem-
onstrating a decrease of 14 or more episodes per week of each of the following: urge 
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incontinence, total incontinence, and micturitions. Using Z-scores, the percentage of 
effectively treated patients was calculated for both fesoterodine and generic oxybu-
tynin ER. Costs included a physician visit for patients failing treatment and the average 
wholesale price of each medication in 2009 US dollars. Data and costs associated with 
each treatment arm were entered into TreeAge Pro 2008 to obtain the cost-effective-
ness ratios for both therapies. RESULTS: Overall cost-effectiveness ratios obtained 
were $375.27 ($297.59/0.793) per effectively treated patient with oxybutynin ER 
compared to $641.67 ($435.01/0.678) per effectively treated patient with fesoterod-
ine. Due to the greater effect and lower cost of oxybutynin ER, an incremental cost-
effectiveness ratio was not necessary. Sensitivity analyses revealed the results to be 
most sensitive to changes in the probability of oxybutynin ER resulting in an effectively 
treated patient. CONCLUSIONS: Based on this decision model, oxybutynin ER is the 
dominant treatment. Third-party payers may want to consider making oxybutynin ER 
a preferred option for their formularies, rather than fesoterodine.
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OBJECTIVES: Overactive bladder (OAB) disease with urinary incontinence is a preva-
lent disorder among millions of women reaping both high burdens in treatment costs 
and in health-related quality of life. Oxybutynin ER and tolterodine ER are two 
anticholinergic therapies that have demonstrated efﬁcacy, but have signiﬁcant adverse 
event proﬁles contributing to long-term discontinuation. No current cost-effectiveness 
analysis has compared these two therapies to the recent release of an additional 
anticholinergic medication, fesoterodine. With three drugs and numerous possible 
drug regimens involving switching between medications, there exists need for eco-
nomic analysis of the costs and QALYs for OAB treatment. The objective of this study 
was to conduct CE analysis using a backwards induction model to compare costs and 
quality-adjusted life years (QALYs) for the following drug regimens: oxybutynin ER, 
tolterodine ER, fesoterodine, oxybutynin switch tolterodine, tolterodine switch oxy-
butynin, and fesoterodine switch tolterodine. METHODS: The CE model costs were 
derived using a societal perspective. The analysis was conducted in women with OAB 
over the age of 45 years old experiencing urinary incontinence and used valued litera-
ture sources of clinical, cost and compliance data. RESULTS: Based on the model 
inputs, the ICER comparing fesoterodine to tolterodine is $65,880/QALY indicating 
that at the current branded price and base case data on clinical effectiveness and 
compliance, fesoterodine is the most cost-effective treatment. Sensitivity and threshold 
analysis indicate that these results are sensitive to changes in the following inputs: 
utility values for adverse events and medication discontinuation rates. With changes 
in these values of 15% and 25 % respectively, tolterodine ER is the most cost-effective 
treatment. CONCLUSIONS: Drug treatment for OAB with urinary incontinence in 
this population with fesoterodine is most cost-effective when compared to other 
anticholingerics and switching regimens. Limitations of this study include data on 
compliance and utility values, which the model is sensitive to.
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OBJECTIVES: We assessed the potential health and economic beneﬁts of reducing the 
main chronic kidney disease risk factor-hypertension. METHODS: A chronic kidney 
disease microsimulation model tracked a nationally representative cohort to project 
their chronic kidney disease outcomes over thiry years in a hypothetical scenario that 
hypertension could be effectively reduced among the cohort. RESULTS: An effective 
hypertension control saved both cost and lives. Relative to status quo, the gain in 
quality adjusted life years from the improved hypertension adherence would be 
1.28 QALYs within 30 years. The total medical cost saving was estimated to be $789 
per capita, largely due to the substantial savings from the downstream spending on 
end stage renal disease. A total of 224 thousand cases of ESRD, 368 thousand cases 
of renal transplant and 248 thousands cardiovascular events could be avoided due to 
the better hypertension control. CONCLUSIONS: Effective hypertension control 
reduced the incidence of chronic kidney disease and adverse outcomes of End Stage 
Renal Disease. The strategy both improves health outcomes of CKD and saves money. 
More public health efforts should be directed to improve the hypertension awareness 
and control as one effective chronic kidney disease prevention strategy.
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OBJECTIVES: Dialysis treatments are performed in 4100 patients in Serbia. At end-
stage renal disease (ESRD)the only correct selection is kidney transplatation. The basic 
aim of research was to compare ratio of costs and effects (CEA) of hemodialysis and 
kidney transplatation in patients at ESRD.It is assumed, that in spite of that kidney 
transplatation is being more desirable than hemodialysis from aspect of lower costs 
and better quality of patient’s life, number of transplantations in Serbia is still modest 
with respect to requirements. METHODS: The life quality was measured by validated 
McGill Questionary. Research has included 150 patients totally, divided in two 
groups: 1) Study group including 50 patients having kidney transplantation performed 
at Clinical Centre of Serbia; and 2) Control Group including 100 patients on hemo-
dialysis at six different Clinical Centres, comparable with respect to sex, age and length 
of treatment with Study group. RESULTS: Effect of kidney transplantation in relation 
to hemodialysis being selection of treatment is expressed in form of incremental ratio 
of costs and effects (ICER). It is clearly evident that the strategy of kidney transplanta-
tion is far more proﬁtable considering the fact that it represents saving of 3132,256.25 
per one year of contribution QALY within the period of 10 years. According to all 
aspects of live quality (physical symptoms and problems, physical well-being, phycho-
logical symptoms, existential well-being and support), difference is statistically impor-
tant in favour of transplant patents. CONCLUSIONS: Out of the effected cost 
calculation it is evident that the costs of patient treatment therapy by hemodialysis at 
end-stage renal disease is far greater than by performing therapy of transplantation 
and maintenance, by almost three and a half times (3.38). Difference in total aspects 
of human life (physical, emotional, social, spiritual and ﬁnancial) between dialysed 
and transplant patients is statistically important and by 18.12% greater in transplant 
patients than in patients being on hemodialysis.
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OBJECTIVES: We compare, through cost-effectiveness and cost-utility analyses, two 
main components of kidney replacement therapy (KRT): hemodialysis (HD) and 
peritoneal dialysis (PD) (including under PD both continuous ambulatory peritoneal 
dialysis [CAPD] and automated peritoneal dialysis [APD]). METHODS: We used a 
simple decision-tree model, a third payer perspective with only direct costs included, 
and a one-year timeline (with no discount). The model incorporated 20 variables, 
including costs obtained from local sources (databases of more than ten thousand 
patients) and epidemiological data both from international published literature, and 
Colombian databases (particularly for treatment-related complications). Utilities (in 
QALY) were obtained from Tufts CEA Registry and discussed with local experts and 
patient panels (for an average of 0.6375 QALY for PD and 0.5950 for HD). RESULTS: 
We estimate that the average annual cost of PD in Colombia in 2008 was US$16,747 
(at September 2009 ofﬁcial exchange rate of Col$2066 per dollar) while HD costs on 
average US$18,199 per year, including in both cases direct costs of treatment-related 
complications but not other disease-related events. Average cost of each QALY gained 
in a dialysis patient in Colombia ranges from US$26,300 in PD to US$30,600 in HD. 
In our sample, PD was also associated with a reduced frequency of hospitalization 
and shorter hospital stays than HD (on average, 5.2 and 6.5 hospital days per year, 
respectively). CONCLUSIONS: In Colombia, costs of KRT are around two times the 
suggested cost-effectiveness threshold of three times the per capita GDP. On average, 
and perhaps in part attributable to different case mix, PD is dominant over HD. The 
model is highly sensitive to patients preferences (expressed in our case in QALYs), 
which suggest PD is particularly valued in independence seeking patients.
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OBJECTIVES: Benign prostatic hyperplasia has a high prevalence and represents an 
important burden on the quality of life of the affected patients. New medical interven-
tions have been added to the more traditional surgical approach. This Markov cost-
utility and cost-effectiveness model, adjusted to the Colombian health care 
environment, represents the decision to treat a hypothetical 60-year-old patient either 
with surgery (transurethral resection or TUR) or with either alpha blockers (αB), 5 
alpha reductase inhibitors (5ARI) or combined therapy (CT). METHODS: We used 
a third party payer perspective, as well as a 5-year timeframe. Effectiveness data were 
taken from international clinical trials, surgical complications were those of the AUA 
(American Urological Association) practice guidelines. All costs were local, combining 
Colombian Social Security Institute prices as well as real costs from a local private 
clinic. Utilities and disutilities were measured in QALY, obtained from Tufts CEA 
registry. Discount rate was 5% for costs and QALYs. RESULTS: The model shows 
that, over the 5-year timeframe, surgery has the lowest average overall cost (US$1573 
at September 2009 ofﬁcial exchange rate of Col$2066 per US$), compared with αB 
(US$3916), 5ARI (US$3156) or CT (US$5232). With respect to surgery, treatment 
with 5ARI is the most cost-effective (US$8426 per additional QALY gained) followed 
by CT (US$12099 per QALY) and αB (US$24,695). Cost per surgery averted was 
US$1810 with 5ARI, US$2531 with αB and US$3935 with CT. CONCLUSIONS: We 
conclude that treatment with 5ARI is “cost-effective” according to international 
standards (less than three times per capita GDP paid for each additional QALY 
gained). The incremental cost-utility ratio of CT is highly sensitive to price of therapy; 
if price of CT were equal to the price of 5ARI, the cost of each additional QALY 
gained would be US$2733.
